Li Zhang

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Yi‐Long Wu, Shun Lü, Ying Cheng et al. · Journal of Thoracic Oncology · 2019 · 358 citations

Medicine, Oncology, Pharmacology +17

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

Nan Chen, Wenfeng Fang, Lin Zhong et al. · Cancer Immunology Immunotherapy · 2017 · 294 citations · Full text

Medicine, Immunology, Oncology +17

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

Yanna Tang, Wenfeng Fang, Yaxiong Zhang et al. · Oncotarget · 2015 · 243 citations · Full text

Medicine, Oncology, Molecular Oncology +14

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer

Wenfeng Fang, Yuxiang Ma, Jiani C. Yin et al. · Clinical Cancer Research · 2019 · 236 citations

Medicine, Molecular Genetics, Oncology +17

The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy

Gui-Zhen Wang, Li Zhang, Xin-Chun Zhao et al. · Nature Communications · 2019 · 219 citations · Full text

Medicine, Immunology, Oncology +17